The Current and Future State of Immune Checkpoint Inhibitors in NSCLC | Supplements and Featured Publications

August 19, 2022

Stephen V. Liu, MD and Neal E. Ready, MD, PhD, discuss the new data with nivolumab plus ipilimumab in treatment-naïve NSCLC and provide commentary on treatment considerations for patients who are eligible to receive these regimens.

August 03, 2022

Neal Edward Ready, MD, PhD, discusses factors to consider when deciding when the use the regimen of nivolumab and ipilimumab plus chemotherapy in metastatic non–small cell lung cancer.

August 02, 2022

Hossein Borghaei, DO, MS, discusses the investigation of nivolumab plus ipilimumab and chemotherapy in patients with metastatic non–small cell lung cancer.

July 22, 2022

Julie R. Brahmer, MD, MSc, discusses how data from the CheckMate 227 trial may affect the treatment landscape for NSCLC and notes the quality-of-life outcomes reported with nivolumab and ipilimumab.

July 21, 2022

Jason Porter, MD, discusses the 3-year follow-up data from the phase 3 CheckMate-9LA trial done in patients with metastatic non–small cell lung cancer.

July 21, 2022

Neal Edward Ready, MD, PhD, discusses the practice implications of nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer.

July 14, 2022

Julie R. Brahmer, MD, MSc, discusses the significance of the long-term survival data of nivolumab plus ipilimumab seen in the phase 3 CheckMate-227 trial in patients with metastatic non–small cell lung cancer.

July 14, 2022

Luis G. Paz-Ares, MD, PhD, discuses the importance of nivolumab plus ipilimumab in the treatment of patients with metastatic non–small cell lung cancer.

June 06, 2022

Patients with metastatic non–small cell lung cancer treated with first-line nivolumab and ipilimumab plus chemotherapy experienced prolonged benefit in overall survival compared with those who received chemotherapy alone.

June 06, 2022

Results of a 5-year analysis of the phase 3 CheckMate 227 trial showed that the combination of nivolumab plus ipilimumab elicited durable overall survival benefit in patients with metastatic non–small cell lung cancer regardless of PD-L1 expression compared with chemotherapy.